Completed PHASE2 INTERVENTIONAL 1-arm NCT00320580

An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen

A Randomized, Open-Label, Multicenter Study Comparing the Bleeding Profile of Ortho Evra (Norelgestromin/Ethinyl Estradiol) Continuous Regimen vs. Ortho Evra Cyclic Regimen

Sponsor: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Conditions Metrorrhagia

Interventions norelgestromin/ethinyl estradiol

Updated 5 times since 2017 Last updated: Jun 30, 2011 Completion: Mar 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metrorrhagia and is currently completed. McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Data source: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.